FDA Not Forgetting Sanofi’s Previous Failed Trial In New Multaq Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks Cardiovascular and Renal Drugs advisory committee to compare Sanofi’s negative dronedarone trial to its new pivotal trial.
You may also be interested in...
Committee Recommends Sanofi’s Multaq For Approval
Despite issues with ATHENA and ANDROMEDA, committee recommends approval of Multaq, but not with the mortality claim Sanofi-Aventis hoped for.
Committee Recommends Sanofi’s Multaq For Approval
Despite issues with ATHENA and ANDROMEDA, committee recommends approval of Multaq, but not with the mortality claim Sanofi-Aventis hoped for.
Rivaroxaban Committee Review May Hinge On Concerns About Off-Label Use
J&J’s oral anticoagulant Xarelto has solid, but not strong, data for limited surgery claims; bleeding is among the safety worries.